GlassScriptPhysician profile
Azim Ebun Surka
NPI 1073626073
$7,657.12
in general payments reported to CMS, 2019-2025
31 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $196 · 2021: $1,218 · 2022: $2,250 · 2023: $1,365 · 2024: $761 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355 · Travel and Lodging: $679 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.33 |
| Travel and Lodging | $679.29 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $3,083.71 | 2021-2025 | Monarch Platform |
| Noah Medical Corporation | $1,074.91 | 2023-2025 | Galaxy |
| Medical Device Business Services, INC. | $904.03 | 2023 | Monarch |
| Pulmonx Corporation | $322.96 | 2019-2022 | |
| Galvanize Therapeutics, INC | $317.92 | 2024-2025 | Aliya System |
| Glaxosmithkline, LLC. | $311.57 | 2019-2025 | Nucala |
| Medtronic, INC. | $235.73 | 2021-2023 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $205.28 | 2019-2025 | Fasenra |
| Inari Medical, INC. | $199.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.59 | 2019-2022 | |
| Vapotherm INC | $155.11 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $141.17 | 2019-2020 | |
| Abiomed | $86.90 | 2019-2020 | |
| Insmed, INC. | $52.26 | 2019-2025 | Brinsupri |
| Mylan Specialty L.P. | $49.68 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $41.71 | 2019 | |
| Genentech USA, INC. | $40.07 | 2019 | |
| Philips North America LLC | $30.27 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $30.01 | 2019-2020 | |
| Genzyme Corporation | $27.43 | 2019 | |
| Resmed Corp | $25.13 | 2019 | |
| Electromed, INC. | $21.12 | 2023 | Smartvest |
| Verona Pharma, INC. | $19.92 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $17.73 | 2022 | |
| United Therapeutics Corporation | $16.05 | 2024 | Tyvaso |
| Edwards Lifesciences Corporation | $15.83 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $14.30 | 2019 | |
| Grifols USA, LLC | $14.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.90 | 2020 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azim Surka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.